RxDoctor Payments Data

Raye-Anne Ayo, MD

Family Medicine · Knoxville, TNNPI 1689699381

Payments from drug & device makers

$3,075in general payments, 2019–2025

Across 182 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$386
  • Takeda Pharmaceuticals U.S.A., Inc.$380
  • AbbVie$339
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
  • Amgen$204
  • Lilly USA, LLC$203
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,01598%
  • Other$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,075 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,477
Medicare patients
134
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$88,757
Repatha SureclickEvolocumab50$44,593
TrulicityDulaglutide31$41,650
EliquisApixaban24$38,208
JardianceEmpagliflozin22$30,029
RybelsusSemaglutide13$23,668
MounjaroTirzepatide19$19,546
Tresiba Flextouch U-200Insulin Degludec16$13,707
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$8,104
ArexvyRsvpref3 Antigen/As01e/Pf14$4,430
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,732
Humalog Kwikpen U-100Insulin Lispro11$2,605
Bupropion XlBupropion Hcl40$1,569
Atorvastatin Calcium148$1,275
Levothyroxine Sodium153$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$386$112,42476 claims
Lilly USA, LLCTrulicity, Mounjaro$203$61,19550 claims
PfizerEliquis$133$38,20824 claims
GSKArexvy, Shingrix$69$7,16226 claims
AbbVieSynthroid$339$75314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →